Compare Amgen, Inc. (AMGN) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Direxion Daily TSLA Bull 2X Shares trades at $12.84. The key difference: Amgen, Inc. pays a 2.77% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and Amgen, Inc. is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| AMGN | TSLL | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $388.16 | $23.03 |
52-Week Low | $271.18 | $10.29 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TSLL is trading at $13.09, up 0.54% with a bearish technical signal from moving averages. Key support levels are at $12 and $11, while resistance sits at $13 and $14. The stock shows neutral oscillator readings with RSI levels around 46-50, indicating balanced momentum. Recent news highlights interest in derivative-based ETF strategies and connections to Tesla's performance.
The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may exist for those speculating on Tesla-related volatility through this ETF, but risks include market volatility and dependency on underlying asset performance. The neutral sentiment from oscillators suggests waiting for clearer directional signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
